Ophthalmology
The Scheie Eye Institute at Penn Medicine is a world leader in patient care and eye and vision research. With nearly 60 full-time physicians and scientists, Penn Medicine is dedicated to advancing the frontiers of ophthalmology in order to prevent blindness and vision loss.
Penn offers numerous advanced diagnostic and treatment services in comprehensive ophthalmology, and the latest programs spanning the full range of primary and subspecialty eye care, including medical and surgical management of the most complex eye disorders.
About Opthalmology at Penn Medicine
The Scheie Eye Institute is consistently in the top five in the nation in research grant awards from the National Eye Institute. Areas of specialty include:
- Corneal diseases
- Dry eye
- Eye movement disorders
- Glaucoma
- Low vision
- Neuro-ophthalmology
- Ocular genetics
- Oculofacial and orbital surgery
- Refractive surgery (LASIK)
- Retinal disorders
- Thyroid eye disease
- Uveitis
- Gene therapy
Other opthalmology services at Penn include:
- The Penn Center for Low Vision Rehabilitation helps patients make the most of vision that cannot be restored further through medical or surgical means.
- The Penn Dry Eye & Ocular Surface Center offers the most advanced care for patients with dry eye, blepharitis and various ocular surface disorders.
- The Penn Eye Care Vision Surgery and Laser Center provides patients with the highest quality refractive surgery care, including laser vision correction.
The Penn Difference
At Penn Medicine, patients benefit from the most advanced diagnosis and treatment options available. This includes personalized medicine that involves using information about individual patients to match or optimize their specific preventive or therapeutic health care needs.
The Scheie Eye Institute is a world leader in treating retinal degenerations including age-related macular degeneration and provides personalized therapies such as gene therapy to treat its patients. Physicians in Penn Medicine's Department of Ophthalmology were among the first to demonstrate proof-of-principle of ocular gene therapy. Through Penn's findings, inherited retinal degenerations have shown sustained visual restoration following gene therapy.
Scientists in Penn's F.M. Kirby Center for Molecular Ophthalmology conduct research on the cellular and molecular biology of vision and eye diseases.
